Emergent BioSolutions

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The firm's products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units include Vaccines and Anti-Infectives, Antibody Therapeutics, Devices, and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Emergent BioSolutions addresses revenue challenges, eyes market expansion opportunities

Emergent BioSolutions navigated revenue challenges in Q4 2022, focusing on core businesses and strategic initiatives with a strong financial outlook for 2023.
The company faces competition and market positioning challenges in the OTC space for NARCAN, while opportunities exist in market expansion and government contracts.
Balancing pricing strategies, securing procurement decisions, and extending credit facility maturity are key focus areas for sustained growth and profitability.
Overall, Emergent BioSolutions demonstrates resilience and adaptability in addressing market challenges while capitalizing on opportunities for growth and market expansion.

Emergent BioSolutions (EBS) excels in Q1 with FDA approvals and strategic sales

Emergent BioSolutions (EBS) delivered a robust Q1 performance with notable achievements in FDA approvals and strategic business decisions. While facing challenges in gross margin changes and insurance coverage discussions, EBS remains focused on growth opportunities and product innovation.

Emergent BioSolutions reports Q2 growth, shifts focus to core products

Emergent BioSolutions' Q2 2023 earnings call highlighted positive financial results, strong NARCAN Nasal Spray sales, and strategic shifts towards core products. The company provided updated guidance for 2023, focusing on revenue expectations and cost-saving measures. Analyst questions centered on revenue breakdown, restructuring efforts, and future growth prospects.

Emergent BioSolutions (EBS) exceeds Q3 expectations, focuses on growth

Emergent BioSolutions (EBS) demonstrated strong financial performance in Q3 2023, exceeding revenue and EBITDA expectations. The company's focus on core products, compliance, and cost reduction initiatives positions it well for future growth. Challenges include a rescheduled earnings release and the need to meet growing demand for NARCAN Nasal Spray.

Emergent BioSolutions reports solid Q4 performance and outlines growth strategies

Emergent BioSolutions showcased strong financial performance and operational progress in Q4 2023, setting the stage for a promising 2024.
The company's strategic focus on debt reduction, quality enhancement, and core product strength bodes well for future growth.
While challenges persist in managing product sales variability and addressing stakeholder inquiries, opportunities for expansion and success are abundant.

Emergent BioSolutions excels in Q1, raises 2024 outlook amid growth prospects

Emergent BioSolutions reported strong Q1 performance, raised profit outlook for 2024, and highlighted growth drivers for key products. The company's strategic actions to reduce costs, improve profitability, and focus on core businesses demonstrate a proactive approach to driving long-term value. Despite challenges like potential generic competition, EBS remains well-positioned to leverage growth opportunities and sustain its positive momentum.

Emergent BioSolutions (EBS) exceeds Q2 guidance, poised for growth

Emergent BioSolutions (EBS) delivered strong Q2 results, exceeding revenue guidance and showcasing operational improvements.
The company's strategic actions, product highlights, and financial performance position it well for future growth and value creation.
Challenges in revenue sustainability and operational changes exist, but opportunities in international expansion, partnerships, and innovation are key drivers.
Overall, Emergent's focus on public health preparedness, opioid crisis solutions, and strategic growth initiatives bode well for its long-term success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

RADNOR, Pa., April 26, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed in the United States District Court for the District of Maryland against Emergent BioSolutions Inc. (NYSE: EBS) ("Emergent") on behalf of those who purchased or acquired Emergent common stock between July 6, 2020 and March 31, 2021 , inclusive (the "Class Period").

Class Action Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against Emergent BioSolutions Inc.

LOS ANGELES--(BUSINESS WIRE)---- $EBS #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Emergent BioSolutions Inc. (“Emergent” or the “Company”) (NYSE: EBS) common stock between July 6, 2020 and March 31, 2021, inclusive (the “Class Period”). Emergent investors have until June 18, 2021 to file a lead plaintiff motion. If you suffered a loss on your Emerg

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Emergent BioSolutions Inc. (EBS) Investors

On Emergent's (EBS) upcoming first-quarter earnings call, investors are likely to focus on the company's update related to re-start of production at its Bayview facility.

What's in Store for Emergent (EBS) This Earnings Season?

Emergent BioSolutions (EBS) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

Moving Average Crossover Alert: Emergent BioSolutions (EBS)

NEW YORK, April 24, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Emergent BioSolutions Inc. (NYSE: EBS) between July 6, 2020 through March 31, 2021, inclusive (the "Class Period"). A class action lawsuit has already been filed.

EBS INVESTOR NOTICE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Emergent BioSolutions Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline - EBS

Radnor, Pennsylvania--(Newsfile Corp. - April 24, 2021) -  The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed in the United States District Court for the District of Maryland against Emergent BioSolutions Inc. (NYSE: EBS) ("Emergent") on behalf of those who purchased or acquired Emergent common stock between July 6, 2020 and March 31, 2021, inclusive (the "Class Period").Deadline Reminder: Investors who...

Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against Emergent BioSolutions Inc. - EBS

SAN DIEGO & GAITHERSBURG, Md.--(BUSINESS WIRE)---- $EBS #ClassAction--Shareholder rights law firm Robbins LLP announces that a purchaser of Emergent BioSolutions Inc (NYSE: EBS) filed a class action complaint against the Company and its officers and directors for alleged violations of the Securities Exchange Act of 1934 between July 6, 2020 and March 31, 2021. Emergent is a specialty biopharmaceutical company that develops vaccines and antibody therapeutics for infectious diseases. If you suffered a loss due to Emer

SHAREHOLDER ALERT: Robbins LLP Announces That Emergent BioSolutions Inc. (EBS) is Being Sued for Misleading Shareholders

BENSALEM, Pa.--(BUSINESS WIRE)---- $EBS #CLASSACTION--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased of Emergent BioSolutions Inc. (“Emergent” or the “Company”) (NYSE: EBS) common stock between July 6, 2020 and March 31, 2021, inclusive (the “Class Period”). Emergent investors have until June 18, 2021 to file a lead plaintiff motion. Investors suffering losses on their Emergent investments are encouraged to contact the Law Offices of Howard G.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Emergent BioSolutions Inc. (EBS) Investors

NEW YORK, April 23, 2021 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Emergent BioSolutions Inc. ("Emergent" or "the Company") (NYSE: EBS) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Emergent securities between July 6, 2020 and March 31, 2021, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/ebs.

EBS Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Emergent BioSolutions Inc. Shareholders of Class Action and Encourages Investors to Contact the Firm

RADNOR, Pa.--(BUSINESS WIRE)---- $EBS #classaction--Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud Class Action Lawsuit Filed Against Emergent BioSolutions Inc. (EBS)

Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud Class Action Lawsuit Filed Against Emergent BioSolutions Inc. (EBS)

LOS ANGELES--(BUSINESS WIRE)---- $EBS #investors--The Law Offices of Frank R. Cruz Announces Investigation of Emergent BioSolutions Inc. (EBS) on Behalf of Investors

The Law Offices of Frank R. Cruz Announces Investigation of Emergent BioSolutions Inc. (EBS) on Behalf of Investors

Emergent Biosolutions (EBS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Emergent Biosolutions (EBS) Earnings Expected to Grow: Should You Buy?

Emergent Biosolutions (EBS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Emergent Biosolutions (EBS) is Poised to Beat Earnings Estimates Again

LOS ANGELES--(BUSINESS WIRE)---- $EBS #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Emergent BioSolutions Inc. (“Emergent” or the “Company”) (NYSE: EBS) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Emergent investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securi

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Emergent BioSolutions Inc. (EBS) on Behalf of Investors

An analyst lowered his price target on the stock.

Why Emergent BioSolutions Stock Is Falling Again Today

Emergent Biosolutions has been in the news lately but for the wrong reasons. Earlier this month, we advised caution on EBS stock when it was revealed that a “human error” in the company's plant resulted in the contamination of a batch of Johnson & Johnson's (NYSE: JNJ) Covid-19 vaccine.

Is The Worst Over For Emergent Biosolutions Stock?

BENSALEM, Pa.--(BUSINESS WIRE)---- $EBS #CLASSACTION--Law Offices of Howard G. Smith announces an investigation on behalf of Emergent BioSolutions Inc. (“Emergent” or the “Company”) (NYSE: EBS) investors concerning the Company's possible violations of federal securities laws. On March 31, 2021, The New York Times published an article reporting that in late February 2021, employees at Emergent's Baltimore manufacturing plant “mixed up” ingredients of the different COVID-19 vaccines, contaminating up to 15 million dos

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Emergent BioSolutions Inc. (EBS) on Behalf of Investors

RADNOR, Pa., April 21, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed in the United States District Court for the District of Maryland against Emergent BioSolutions Inc. (NYSE: EBS) ("Emergent") on behalf of those who purchased or acquired Emergent common stock between July 6, 2020 and March 31, 2021 , inclusive (the "Class Period").

EBS CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud Class Action Lawsuit Filed Against Emergent BioSolutions Inc.

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Emergent BioSolutions Inc. (NYSE: EBS) between July 6, 2020 through March 31, 2021, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 18, 2021. SO WHAT: If you purchased Emergent BioSolutions securities during th

EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Emergent BioSolutions Inc. Investors with Losses to Secure Counsel Before Important Deadline – EBS

Boston, Massachusetts--(Newsfile Corp. - April 21, 2021) - The Thornton Law Firm alerts investors that a class action lawsuit has been filed on behalf of investors of Emergent BioSolutions Inc. (NYSE: EBS). The case is currently in the lead plaintiff stage. Investors who purchased EBS stock or other securities between July 6, 2020 and March 31, 2021 may contact the Thornton Law Firm's investor protection team by visiting www.tenlaw.com/cases/Emergent to submit their information. Investors may...

EMERGENT BIOSOLUTIONS INVESTOR ALERT: Shareholder Lawsuit Filed

GAITHERSBURG, Md., April 21, 2021 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration (FDA) has completed its inspection of Emergent BioSolutions' (NYSE:EBS) Baltimore-Bayview facility and provided specific feedback. Given the heightened focus on this facility, the FDA has proactively shared its findings to keep the public, policymakers and all other stakeholders informed. The issuance of findings by the FDA is normal following a facility inspection and provides direction on the necessary steps to improve operations. Emergent is committed to working with the FDA and Johnson & Johnson to quickly resolve the issues identified.

Statement on Issuance of Form FDA 483 at Emergent Bayview Facility

Johnson & Johnson

The FDA concluded its inspection of Emergent BioSolutions Inc's (NYSE: EBS) troubled vaccine manufacturing plant in Baltimore after it stopped production on Monday. The agency released a couple of blistering observations on the cross-contamination, sanitary issues, and lack of staff training that caused ingredient mix-ups at the facility.

FDA's Inspection Of Emergent's COVID-19 Vaccine Baltimore Plant Outlines Concerns About Sanitary Conditions, Employee Training

The report said the facility did not properly train personnel or adequately clean the warehouse.

FDA Issues Scathing Report Of Baltimore Warehouse Where Johnson & Johnson Vaccines Were Ruined

Shares of Emergent BioSolutions Inc. were up 1.3% in trading on Wednesday after the Food and Drug Administration said it inspected a plant in Baltimore that had been scheduled to begin producing Johnson & Johnson's COVID-19 vaccine after reports emerged of cross-contamination in vaccine production there. J&J confirmed several weeks ago that quality standards had not been met at the Emergent facility.

FDA inspection of Emergent's COVID-19 vaccine plant identifies 'potential quality issues'

The Food and Drug Administration said Wednesday a Baltimore plant that ruined millions of Johnson & Johnson Covid-19 vaccine doses was unsanitary and unsuitable to manufacture the shots.

News for Emergent BioSolutions Stock (EBS)